FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895579856> ?p ?o ?g. }

• W2895579856 endingPage "239" @default.
• W2895579856 startingPage "231" @default.
• W2895579856 abstract "Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC). It is unknown whether this treatment strategy is appropriate for patients who progress to MIBC after treatment for prior noninvasive disease (secondary MIBC).To determine whether clinical and genomic differences exist between primary and secondary MIBC treated with NAC and RC.Clinicopathologic outcomes were compared between 245 patients with clinical T2-4aN0M0-stage primary MIBC and 43 with secondary MIBC treated with NAC and RC at Memorial Sloan Kettering Cancer Center (MSKCC) from 2001 to 2015. Genomic differences were assessed in a retrospective cohort of 385 prechemotherapy specimens sequenced by whole-exome or targeted exon capture by the Cancer Genome Atlas or at MSKCC. Findings were confirmed in an independent validation cohort of 94 MIBC patients undergoing prospective targeted exon sequencing at MSKCC.Pathologic response rates, recurrence-free survival (RFS), bladder cancer-specific survival (CSS), and overall survival (OS) were measured. Differences in somatic genomic alteration rates were compared using Fisher's exact test and the Benjamini-Hochberg false discovery rate method.Patients with secondary MIBC had lower pathologic response rates following NAC than those with primary MIBC (univariable: 26% vs 45%, multivariable: odds ratio=0.4 [95% confidence interval=0.18-0.84] p=0.02) and significantly worse RFS, CSS, and OS. Patients with secondary MIBC treated with NAC had worse CSS compared with cystectomy alone (p=0.002). In a separate genomic analysis, we detected significantly more likely deleterious somatic ERCC2 missense mutations in primary MIBC tumors in both the discovery (10.9% [36/330] vs 1.8% [1/55], p=0.04) and the validation (15.7% [12/70] vs 0% [0/24], p=0.03) cohort.Patients with secondary MIBC treated with NAC had worse clinical outcomes than similarly treated patients with primary MIBC. ERCC2 mutations predicted to result in increased cisplatin sensitivity were enriched in primary versus secondary MIBC. Prospective validation is still needed, but given the lack of clinical benefit with cisplatin-based NAC in patients with secondary MIBC, upfront RC or enrollment in clinical trials should be considered.A retrospective cohort study of patients with primary and secondary muscle-invasive bladder cancer (MIBC) treated with chemotherapy before surgical removal of the bladder identified lower response rates and shorter survival in patients with secondary MIBC. Tumor genetic sequencing of separate discovery and validation cohorts revealed that chemotherapy-sensitizing DNA damage repair gene mutations occur predominantly in primary MIBC tumors and may underlie the greater sensitivity of primary MIBC to chemotherapy. Prospective validation is still needed, but patients with secondary MIBC may derive greater benefit from upfront surgery or enrollment in clinical trials rather than from standard chemotherapy." @default.
• W2895579856 created "2018-10-12" @default.
• W2895579856 creator A5004669792 @default.
• W2895579856 creator A5013778834 @default.
• W2895579856 creator A5015695327 @default.
• W2895579856 creator A5019379068 @default.
• W2895579856 creator A5021762206 @default.
• W2895579856 creator A5022477189 @default.
• W2895579856 creator A5026511535 @default.
• W2895579856 creator A5029777782 @default.
• W2895579856 creator A5033054923 @default.
• W2895579856 creator A5033125884 @default.
• W2895579856 creator A5035094762 @default.
• W2895579856 creator A5035462260 @default.
• W2895579856 creator A5037092952 @default.
• W2895579856 creator A5048541532 @default.
• W2895579856 creator A5053263729 @default.
• W2895579856 creator A5053547168 @default.
• W2895579856 creator A5064203357 @default.
• W2895579856 creator A5064884168 @default.
• W2895579856 creator A5067264659 @default.
• W2895579856 creator A5069771802 @default.
• W2895579856 creator A5082249915 @default.
• W2895579856 creator A5086957919 @default.
• W2895579856 creator A5091442876 @default.
• W2895579856 date "2019-02-01" @default.
• W2895579856 modified "2023-10-10" @default.
• W2895579856 title "Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy" @default.
• W2895579856 cites W1711618159 @default.
• W2895579856 cites W1893588230 @default.
• W2895579856 cites W1965514945 @default.
• W2895579856 cites W1971099042 @default.
• W2895579856 cites W1975918912 @default.
• W2895579856 cites W1989141974 @default.
• W2895579856 cites W1998421334 @default.
• W2895579856 cites W2033775272 @default.
• W2895579856 cites W2035297454 @default.
• W2895579856 cites W2049833612 @default.
• W2895579856 cites W2058833787 @default.
• W2895579856 cites W2067964015 @default.
• W2895579856 cites W2073175347 @default.
• W2895579856 cites W2103561213 @default.
• W2895579856 cites W2116299167 @default.
• W2895579856 cites W2131178190 @default.
• W2895579856 cites W2149441684 @default.
• W2895579856 cites W2170518050 @default.
• W2895579856 cites W223909586 @default.
• W2895579856 cites W2289712604 @default.
• W2895579856 cites W2308167615 @default.
• W2895579856 cites W2318233342 @default.
• W2895579856 cites W2343368549 @default.
• W2895579856 cites W2432541865 @default.
• W2895579856 cites W2498471190 @default.
• W2895579856 cites W2550856922 @default.
• W2895579856 cites W2604535399 @default.
• W2895579856 cites W2613362156 @default.
• W2895579856 cites W2621022579 @default.
• W2895579856 cites W2763670669 @default.
• W2895579856 doi "https://doi.org/10.1016/j.eururo.2018.09.002" @default.
• W2895579856 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6339572" @default.
• W2895579856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30290956" @default.
• W2895579856 hasPublicationYear "2019" @default.
• W2895579856 type Work @default.
• W2895579856 sameAs 2895579856 @default.
• W2895579856 citedByCount "95" @default.
• W2895579856 countsByYear W28955798562019 @default.
• W2895579856 countsByYear W28955798562020 @default.
• W2895579856 countsByYear W28955798562021 @default.
• W2895579856 countsByYear W28955798562022 @default.
• W2895579856 countsByYear W28955798562023 @default.
• W2895579856 crossrefType "journal-article" @default.
• W2895579856 hasAuthorship W2895579856A5004669792 @default.
• W2895579856 hasAuthorship W2895579856A5013778834 @default.
• W2895579856 hasAuthorship W2895579856A5015695327 @default.
• W2895579856 hasAuthorship W2895579856A5019379068 @default.
• W2895579856 hasAuthorship W2895579856A5021762206 @default.
• W2895579856 hasAuthorship W2895579856A5022477189 @default.
• W2895579856 hasAuthorship W2895579856A5026511535 @default.
• W2895579856 hasAuthorship W2895579856A5029777782 @default.
• W2895579856 hasAuthorship W2895579856A5033054923 @default.
• W2895579856 hasAuthorship W2895579856A5033125884 @default.
• W2895579856 hasAuthorship W2895579856A5035094762 @default.
• W2895579856 hasAuthorship W2895579856A5035462260 @default.
• W2895579856 hasAuthorship W2895579856A5037092952 @default.
• W2895579856 hasAuthorship W2895579856A5048541532 @default.
• W2895579856 hasAuthorship W2895579856A5053263729 @default.
• W2895579856 hasAuthorship W2895579856A5053547168 @default.
• W2895579856 hasAuthorship W2895579856A5064203357 @default.
• W2895579856 hasAuthorship W2895579856A5064884168 @default.
• W2895579856 hasAuthorship W2895579856A5067264659 @default.
• W2895579856 hasAuthorship W2895579856A5069771802 @default.
• W2895579856 hasAuthorship W2895579856A5082249915 @default.
• W2895579856 hasAuthorship W2895579856A5086957919 @default.
• W2895579856 hasAuthorship W2895579856A5091442876 @default.
• W2895579856 hasBestOaLocation W28955798562 @default.
• W2895579856 hasConcept C121608353 @default.
• W2895579856 hasConcept C126322002 @default.
• W2895579856 hasConcept C143998085 @default.

• next